Cognition Therapeutics appears in NEXT Pittsburgh

Posted by & filed under News.

Cognition Therapeutics aims to stop memory loss with breakthrough Alzheimer’s drug Cognition Therapeutics, a Pittsburgh company that specializes in treating neurocognitive disorders, has taken the next step to developing an innovative new drug for treating Alzheimer’s disease. Link to the article

Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease

Posted by & filed under News.

PITTSBURGH, Dec. 13, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the initiation of U.S. clinical testing of CT1812, its proprietary first-in-class, orally available small molecule therapeutic being developed for the treatment of… Read more »

Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Posted by & filed under News.

PITTSBURGH, Dec. 5, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that its poster focused on CT1812 safety data, its proprietary first-in-class, orally available small molecule in development for the treatment of Alzheimer’s disease,… Read more »

Society for Neuroscience 2016 Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics”

Posted by & filed under News.

PITTSBURGH, Nov. 30, 2016 /PRNewswire/ — Susan Catalano, Ph.D., founder and CSO of Cognition Therapeutics, Inc., (CogRx) a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, chaired the Nanosymposium titled “sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” at the recent Society for… Read more »

CogRx Sees Lilly Solanezumab Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease

Posted by & filed under News.

PITTSBURGH, Nov. 23, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today provided its comments and perspective on the Phase 3 clinical trial data of Eli Lilly’s Alzheimer’s disease medicine, solanezumab. “These results, while disappointing… Read more »

CogRx Founder and CSO, Dr. Susan Catalano, will co-chair nanosymposium at the Society for Neuroscience 2016 Annual Meeting

Posted by & filed under News.

Cognition Therapeutics (CogRx) Founder and CSO, Dr. Susan Catalano, will co-chair the nanosymposium titled, “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” at the Society for Neuroscience 2016 Annual Meeting in San Diego. The nanosymposium will be held on Wednesday, November 16, 2016 and will be co-chaired by Dr. Bob Mach, Britton Chance Professor of Radiology,… Read more »

Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812

Posted by & filed under News.

— The first small molecule drug candidate showing ability to restore memory to normal in Alzheimer’s disease models — PITTSBURGH, Nov. 11, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the first… Read more »

Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO

Posted by & filed under News.

PITTSBURGH, Oct. 28, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer of the company. Mr. Moch will also join the company’s Board of Directors. Mr. Moch brings to Cognition more than 25 years of experience in creating,… Read more »

CogRx appears in BioPharma Dealmakers

Posted by & filed under News.

Focusing on synaptic protection in Alzheimer’s Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule designed to halt the initiation and progression of Alzheimer’s disease. Link to the article